

Ilumya® (tildrakizumab-asmn)

Help Us Better Understand the Possible Effects of Ilumya® in Pregnancy

Many people need to take medication during pregnancy to appropriately manage a chronic health condition. In some cases, avoiding or stopping medication use during pregnancy may be more harmful than taking medication. Yet fewer than 10% of medications have enough information to determine their safety for use in pregnancy — this is where you come in!

MotherToBaby is currently enrolling people who are pregnant in a study examining the use of Ilumya® (tildrakizumab-asmn) to treat psoriasis during pregnancy.

“There is a huge need to generate more info for all of the drugs that people who are pregnant need to take.”

--- Christina Chambers, PhD, MPH, Lead Investigator, MotherToBaby Pregnancy Studies

Are you currently pregnant? Did you take Ilumya® at any point in your current pregnancy? If you answered “yes” to both of these questions, then you have the opportunity to help us learn more about Ilumya® use in pregnancy.

Will you take the step and become our partner? Make an impact on the health of future families today by joining our Ilumya® & Pregnancy Study!

JOIN A STUDY

REFER A PATIENT

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, August 12, 2019.

Ilumya® (tildrakizumab-asmn)

This Study is now closed to recruitment.

Thank you for your interest, but unfortunately, we are no longer enrolling participants in this study. However, you may be eligible to participate in one of our other ongoing studies. Fill out your information using our [Join a Study](#) form, and a member of our team will contact you.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, August 12, 2019.

Ilumya® (tildrakizumab-asmn)

Help Us Understand the Effects of Eczema in Pregnancy

Many people need to take medication during pregnancy to appropriately manage their moderate-to-severe eczema (atopic dermatitis). Yet fewer than 10% of medications have enough information to determine their safety for use in pregnancy — this is where we need you as our partner!

“There is a huge need to generate more info for all of the drugs that people who are pregnant need to take.”

--- Christina Chambers, PhD, MPH, Lead Investigator, MotherToBaby Pregnancy Studies

Do you have moderate-to-severe eczema? Are you currently pregnant? If you answered “yes” to both of these questions, you may be able to help us advance our knowledge of how moderate-to-severe eczema and its management can affect a pregnancy and a developing baby.

Will you take the step and become our partner? Make an impact on the health of future families today by joining our Eczema & Pregnancy Study!

JOIN NOW

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, August 12, 2019.

Ilumya® (tildrakizumab-asmn)

This study is now closed to recruitment.

Thank you for your interest, but unfortunately we are no longer enrolling participants in this study. However, you may be eligible to participate in one of our other ongoing studies. Fill out our information form by clicking the Make A Difference button below, and a member of our team will contact you.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, August 12, 2019.

Ilumya® (tildrakizumab-asmn)

Help Us Better Understand the Possible Effects of Tremfya® in Pregnancy

Many people need to take medication during pregnancy to appropriately manage a chronic health condition. In some cases, avoiding or stopping medication use during pregnancy may be more harmful than taking medication. Yet fewer than 10% of medications have enough information to determine their safety for use in pregnancy — this is where you

come in!

MotherToBaby is currently enrolling people in a study examining the use of Tremfya® (guselkumab) to treat psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis during pregnancy.

"There is a huge need to generate more info for all of the drugs that people who are pregnant need to take."

--- Christina Chambers, PhD, MPH, Lead Investigator, MotherToBaby Pregnancy Studies

Are you currently pregnant? Did you take Tremfya® at any point in your current pregnancy? If you answered "yes" to both of these questions, then you have the opportunity to help us learn more about Tremfya® use in pregnancy.

Will you take the step and become our partner? Make an impact on the health of future families today by joining our Tremfya® & Pregnancy Study!

JOIN A STUDY

REFER A PATIENT

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, August 12, 2019.